Recent discussions on X about Mineralys Therapeutics (MLYS) have been buzzing with interest following the company's announcement of a $175 million public stock offering and promising Phase 3 trial results for its hypertension drug, lorundrostat. Many users have noted the significant surge in stock price, with some pointing to a competitor's positive trial results as a potential catalyst for further attention on Mineralys. The insider buying activity by a major director, involving over a million shares, has also fueled conversations about confidence in the company's future.
Additionally, posts on X have highlighted the potential efficacy and safety of lorundrostat, with some speculating on possible business deals or partnerships stemming from these developments. The sentiment is further shaped by analyst reiterations of positive ratings, which have caught the eye of investors tracking the stock. While the stock offering initially led to a dip in after-hours trading, the overall tone on the platform remains focused on the long-term potential of Mineralys’ clinical advancements.
Note: This discussion summary was generated from an AI condensation of post data.
Mineralys Therapeutics Insider Trading Activity
Mineralys Therapeutics insiders have traded $MLYS stock on the open market 23 times in the past 6 months. Of those trades, 6 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $MLYS stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 2 purchases buying 2,472,766 shares for an estimated $47,499,981 and 0 sales.
- SRINIVAS AKKARAJU has made 2 purchases buying 1,188,235 shares for an estimated $23,099,992 and 0 sales.
- BIOCAPITAL GP, LLC SAMSARA purchased 600,000 shares for an estimated $8,100,000
- BRIAN TAYLOR SLINGSBY purchased 259,259 shares for an estimated $3,499,996
- DAVID MALCOM RODMAN (Chief Medical Officer) has made 0 purchases and 9 sales selling 112,600 shares for an estimated $1,696,764.
- ADAM SCOTT LEVY (CFO and Secretary) has made 0 purchases and 6 sales selling 95,193 shares for an estimated $1,362,615.
- JON CONGLETON (Chief Executive Officer) has made 0 purchases and 2 sales selling 31,203 shares for an estimated $417,233.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Mineralys Therapeutics Hedge Fund Activity
We have seen 118 institutional investors add shares of Mineralys Therapeutics stock to their portfolio, and 64 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 2,899,020 shares (+inf%) to their portfolio in Q2 2025, for an estimated $39,223,740
- TCG CROSSOVER MANAGEMENT, LLC removed 2,470,265 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $33,422,685
- ADAMS STREET PARTNERS LLC removed 1,129,807 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $17,941,335
- STATE STREET CORP added 923,379 shares (+177.5%) to their portfolio in Q2 2025, for an estimated $12,493,317
- ORBIMED ADVISORS LLC added 760,351 shares (+inf%) to their portfolio in Q2 2025, for an estimated $10,287,549
- JENNISON ASSOCIATES LLC removed 743,711 shares (-37.6%) from their portfolio in Q2 2025, for an estimated $10,062,409
- BLACKROCK, INC. added 647,733 shares (+26.4%) to their portfolio in Q2 2025, for an estimated $8,763,827
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Mineralys Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $MLYS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/08/2025
- B of A Securities issued a "Buy" rating on 08/28/2025
To track analyst ratings and price targets for Mineralys Therapeutics, check out Quiver Quantitative's $MLYS forecast page.
Mineralys Therapeutics Price Targets
Multiple analysts have issued price targets for $MLYS recently. We have seen 3 analysts offer price targets for $MLYS in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $42.0 on 09/08/2025
- Dennis Ding from Jefferies set a target price of $26.0 on 09/03/2025
- Greg Harrison from B of A Securities set a target price of $43.0 on 08/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
